Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab deruxtecan in HER2-overexpressing or HER2-mutated metastatic NSCLC
NL-OMON54783Phase 2Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Objective response rate. Started Nov 2018; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON54783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54783.